|
|||||
|
|
Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma,a case study for an approval based on a single-arm combination trial |
|
| Affiliation: | 1. MorphoSys AG, Planegg, Germany;2. European Consulting & Contracting in Oncology, Trier, Germany;3. MorphoSys US Inc., Boston, MA, USA;4. Incyte Biosciences International Sarl, Morges, Switzerland |
| Abstract: |  |
| Keywords: | Real-world data B-cell lymphoma Tafasitamab Lenalidomide Orphan drug Drug approval |
| 本文献已被 ScienceDirect 等数据库收录！ | |